Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for preparing tumor-specific DC vaccine by applying mononuclear cells in umbilical cord blood

A tumor-specific, nuclear cell technology, applied in blood/immune system cells, animal cells, anti-tumor drugs, etc., can solve the problems of limiting clinical application, limiting the mass production of DC vaccines, industrial production of DC vaccine preparations, etc.

Active Publication Date: 2013-11-27
玥特农生物科技河北有限责任公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the individual characteristics of PBMC-derived DCs (PBMC-DCs), clinical applications are limited, especially the mass production of DC vaccines and the industrial production of DC vaccine preparations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing tumor-specific DC vaccine by applying mononuclear cells in umbilical cord blood
  • Method for preparing tumor-specific DC vaccine by applying mononuclear cells in umbilical cord blood
  • Method for preparing tumor-specific DC vaccine by applying mononuclear cells in umbilical cord blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] The preparation method of DC vaccine prepared by monocytes derived from umbilical cord blood, the steps are as follows:

[0068] Step 1. Preparation of autologous tumor-associated whole antigen:

[0069] ①. Fresh tumor tissue resected by surgery: take 0.3-1.0 cm of tissue around the tumor (to avoid necrotic tissue in the center of the tumor) 3 (It can be stored in liquid nitrogen or -80°C refrigerator for later use), cut off the surrounding non-tumor tissue, washed 3-5 times with gentamicin-normal saline, cut into pieces, grinded with a 300-mesh steel mesh to prepare a single-cell suspension, and freeze-thawed repeatedly The tumor cell lysate was prepared by the method, and the protein was quantified after passing through the mesh for later use.

[0070] ②Tumor cells obtained from pleural and ascites: take 1500-2000ml of pleural and ascites, centrifuge at 1200rpm, wash and centrifuge with normal saline for 3 times, pass through a 300-mesh steel mesh to obtain tumor sin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for preparing a tumor-specific DC vaccine by applying mononuclear cells of umbilical cord blood. The method comprises (1) a step of preparing autologous tumor-related holoantigen; (2) a step of obtaining the umbilical cord blood; (3) a step of obtaining the mononuclear cells derived from the umbilical cord blood; (4) a step of performing induction culture for a precursor DC of the mononuclear cells derived from the umbilical cord blood; (5) a step of performing amplification and culture of an immature DC; and (6) a step of preparing the DC vaccine.

Description

technical field [0001] The invention relates to a preparation method of a vaccine, in particular to a method for preparing a tumor-specific DC vaccine by using umbilical cord blood mononuclear cells. Background technique [0002] Cellular immunotherapy of tumors mainly relies on DC-induced T cell immunity. DC is a professional antigen-presenting cell in the human body. Therefore, in tumor immunotherapy, it undertakes the important function of ingesting and processing tumor antigens, and presenting antigen information to T cells, thereby initiating tumor-specific T cell immunity. [0003] DC cells currently used in clinical practice are mainly derived from peripheral blood mononuclear cells (PBMC), and are mainly used in individualized cellular immunotherapy. Due to the individual characteristics of PBMC-derived DC (PBMC-DC), clinical applications are limited, especially the mass production of DC vaccines and the industrial production of DC vaccine preparations. [0004] Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C12N5/078
Inventor 蔡建辉刘刚高飞
Owner 玥特农生物科技河北有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com